CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Oxcarbazepine

奥卡西平 杂质对照品Oxcarbazepine Impurities

EP37 个杂质条目37 impurity entries

本页汇总 奥卡西平 的 37 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 37 impurity reference standards of Oxcarbazepine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 奥卡西平(Oxcarbazepine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesAppraisal of the greenness profile of a chromatographic method for the simultaneous estimation of carbamazepine and oxcarbazepine, along with two potential impurities and three formulation excipients
    RSC advances · 2021 · Abdelwahab NS, Abdelrahman MM  ·  PMID 35423303  ·  DOI
  2. 杂质研究Impurity studiesValidated stability indicating reverse phase liquid chromatography method for oxcarbazepine and its degradation products with greenness evaluation
    Scientific reports · 2026 · Mestareehi A  ·  PMID 42744857  ·  DOI
  3. 杂质研究Impurity studiesMulti-heteroatom-doping promotes molecular oxygen activation on polymeric carbon nitride for simultaneous generation of H(2)O(2) and degradation of oxcarbazepine
    Nanoscale · 2023 · Chen D et al.  ·  PMID 37376986  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of an enantioselective SFC-MS/MS method for simultaneous separation and quantification of oxcarbazepine and its chiral metabolites in beagle dog plasma
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2016 · Yang Z et al.  ·  PMID 27003707  ·  DOI
  5. 分析方法Analytical MethodsQuantification of Oxcarbazepine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
    Methods in molecular biology (Clifton, N.J.) · 2024 · Johnson-Davis KL, Thomas RL  ·  PMID 38036839  ·  DOI

奥卡西平 —— 原料药与杂质对照品Oxcarbazepine — drug substance & impurities

共 38 个条目(含原料药本体)38 items incl. the drug substance
Oxcarbazepine structure
EP原料药 APIAPI
奥卡西平Oxcarbazepine
Oxcarbazepine
CAS No.28721-07-5
Chemical FormulaC15H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 2(Oxcarbazepine EP Impurity B) structure
EPB
奥卡西平杂质2(奥卡西平EP杂质B)Oxcarbazepine Impurity 2(Oxcarbazepine EP Impurity B)
Oxcarbazepine Impurity 2(Oxcarbazepine EP Impurity B)
CAS No.28721-09-7
Chemical FormulaC16H14N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 3(Oxcarbazepine EP Impurity C) structure
EPC
奥卡西平杂质3(奥卡西平EP杂质C)Oxcarbazepine Impurity 3(Oxcarbazepine EP Impurity C)
Oxcarbazepine Impurity 3(Oxcarbazepine EP Impurity C)
CAS No.21737-58-6
Chemical FormulaC14H11NO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 4(Oxcarbazepine EP Impurity D) structure
EPD
奥卡西平杂质4(奥卡西平EP杂质D)Oxcarbazepine Impurity 4(Oxcarbazepine EP Impurity D)
Oxcarbazepine Impurity 4(Oxcarbazepine EP Impurity D)
CAS No.19579-83-0
Chemical FormulaC14H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 5(Oxcarbazepine EP Impurity E) structure
EPE
奥卡西平杂质5(奥卡西平EP杂质E)Oxcarbazepine Impurity 5(Oxcarbazepine EP Impurity E)
Oxcarbazepine Impurity 5(Oxcarbazepine EP Impurity E)
CAS No.256-96-2
Chemical FormulaC14H11N
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 6(Oxcarbazepine EP Impurity F) structure
EPF
奥卡西平杂质6(奥卡西平EP杂质F)Oxcarbazepine Impurity 6(Oxcarbazepine EP Impurity F)
Oxcarbazepine Impurity 6(Oxcarbazepine EP Impurity F)
CAS No.28721-08-6
Chemical FormulaC16H12ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 7(Oxcarbazepine EP Impurity G) structure
EPG
奥卡西平杂质7(奥卡西平EP杂质G)Oxcarbazepine Impurity 7(Oxcarbazepine EP Impurity G)
Oxcarbazepine Impurity 7(Oxcarbazepine EP Impurity G)
CAS No.15882-79-8
Chemical FormulaC17H17NO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 8(Oxcarbazepine EP Impurity H) structure
EPH
奥卡西平杂质8(奥卡西平EP杂质H)Oxcarbazepine Impurity 8(Oxcarbazepine EP Impurity H)
Oxcarbazepine Impurity 8(Oxcarbazepine EP Impurity H)
CAS No.4698-11-7
Chemical FormulaC15H13NO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 9(Oxcarbazepine EP Impurity I) structure
EPI
奥卡西平杂质9(奥卡西平EP杂质I)Oxcarbazepine Impurity 9(Oxcarbazepine EP Impurity I)
Oxcarbazepine Impurity 9(Oxcarbazepine EP Impurity I)
CAS No.537693-29-1
Chemical FormulaC15H10N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 10(Oxcarbazepine EP Impurity K) structure
EPK
奥卡西平杂质10(奥卡西平EP杂质K)Oxcarbazepine Impurity 10(Oxcarbazepine EP Impurity K)
Oxcarbazepine Impurity 10(Oxcarbazepine EP Impurity K)
CAS No.1346601-76-0
Chemical FormulaC16H12N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 11(Oxcarbazepine EP Impurity L) structure
EPL
奥卡西平杂质11(奥卡西平EP杂质L)Oxcarbazepine Impurity 11(Oxcarbazepine EP Impurity L)
Oxcarbazepine Impurity 11(Oxcarbazepine EP Impurity L)
CAS No.2642430-28-0
Chemical FormulaC17H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 12(Oxcarbazepine EP Impurity M) structure
EPM
奥卡西平杂质12(奥卡西平EP杂质M)Oxcarbazepine Impurity 12(Oxcarbazepine EP Impurity M)
Oxcarbazepine Impurity 12(Oxcarbazepine EP Impurity M)
CAS No.2642430-32-6
Chemical FormulaC30H22N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine-d4A structure
—
奥卡西平-d4AOxcarbazepine-d4A
Oxcarbazepine-d4A
CAS No.1020719-71-4
Chemical FormulaC15H8D4N2O2
Purity>95%询价On request
10mg25mg50mg100mg
N-Acetyl Oxcarbazepine Impurity structure
—
N-乙酰基奥卡西平杂质N-Acetyl Oxcarbazepine Impurity
N-Acetyl Oxcarbazepine Impurity
CAS No.28291-63-6
Chemical FormulaC16H13NO2
Purity>95%现货In stock
10mg25mg50mg100mg
Oxcarbazepine Impurity 13 structure
13
奥卡西平杂质13Oxcarbazepine Impurity 13
Oxcarbazepine Impurity 13
CAS No.578-95-0
Chemical FormulaC13H9NO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 14 structure
14
奥卡西平杂质14Oxcarbazepine Impurity 14
Oxcarbazepine Impurity 14
CAS No.78880-65-6
Chemical FormulaC15H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 15 structure
15
奥卡西平杂质15Oxcarbazepine Impurity 15
Oxcarbazepine Impurity 15
CAS No.2642430-30-4
Chemical FormulaC16H13N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 17 structure
17
奥卡西平杂质17Oxcarbazepine Impurity 17
Oxcarbazepine Impurity 17
CAS No.17070-45-0
Chemical FormulaC19H21Cl2N3O
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 18 structure
18
奥卡西平杂质18Oxcarbazepine Impurity 18
Oxcarbazepine Impurity 18
CAS No.1159977-54-4
Chemical FormulaC15H12N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 19 structure
19
奥卡西平杂质19Oxcarbazepine Impurity 19
Oxcarbazepine Impurity 19
CAS No.186694-22-4
Chemical FormulaC18H18N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 20 structure
20
奥卡西平杂质20Oxcarbazepine Impurity 20
Oxcarbazepine Impurity 20
CAS No.1798004-39-3
Chemical FormulaC15H10Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 21 structure
21
奥卡西平杂质21Oxcarbazepine Impurity 21
Oxcarbazepine Impurity 21
CAS No.113952-20-8
Chemical FormulaC15H11BrN2O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 22 structure
22
奥卡西平杂质22Oxcarbazepine Impurity 22
Oxcarbazepine Impurity 22
CAS No.113952-21-9
Chemical FormulaC17H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 23 structure
23
奥卡西平杂质23Oxcarbazepine Impurity 23
Oxcarbazepine Impurity 23
CAS No.1260595-39-8
Chemical FormulaC21H20N2O8
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 71 structure
71
奥卡西平杂质71Oxcarbazepine Impurity 71
Oxcarbazepine Impurity 71
CAS No.104839-39-6
Chemical FormulaC15H12N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 72 structure
72
奥卡西平杂质72Oxcarbazepine Impurity 72
Oxcarbazepine Impurity 72
CAS No.33948-20-8
Chemical FormulaC15H11BrClNO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 73 structure
73
奥卡西平杂质73Oxcarbazepine Impurity 73
Oxcarbazepine Impurity 73
CAS No.885-23-4
Chemical FormulaC14H9NO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 77 structure
77
奥卡西平杂质77Oxcarbazepine Impurity 77
Oxcarbazepine Impurity 77
CAS No.35079-97-1
Chemical FormulaC15H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 78 structure
78
奥卡西平杂质78Oxcarbazepine Impurity 78
Oxcarbazepine Impurity 78
CAS No.58955-94-5
Chemical FormulaC15H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 83 structure
83
奥卡西平杂质83Oxcarbazepine Impurity 83
Oxcarbazepine Impurity 83
CAS No.34124-14-6
Chemical FormulaC14H16N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 84 structure
84
奥卡西平杂质84Oxcarbazepine Impurity 84
Oxcarbazepine Impurity 84
CAS No.1795772-52-9
Chemical FormulaC14H14N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 88 structure
88
奥卡西平杂质88Oxcarbazepine Impurity 88
Oxcarbazepine Impurity 88
CAS No.98253-74-8
Chemical FormulaC16H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 90 structure
90
奥卡西平杂质90Oxcarbazepine Impurity 90
Oxcarbazepine Impurity 90
CAS No.866873-98-5
Chemical FormulaC15H10Br3NO
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 91 structure
91
奥卡西平杂质91Oxcarbazepine Impurity 91
Oxcarbazepine Impurity 91
CAS No.5697-85-8
Chemical FormulaC14H15N
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 92 structure
92
奥卡西平杂质92Oxcarbazepine Impurity 92
Oxcarbazepine Impurity 92
CAS No.10464-40-1
Chemical FormulaC16H16N2O
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 95 structure
95
奥卡西平杂质95Oxcarbazepine Impurity 95
Oxcarbazepine Impurity 95
CAS No.28291-63-7
Chemical FormulaC20H11ClFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 96 structure
96
奥卡西平杂质96Oxcarbazepine Impurity 96
Oxcarbazepine Impurity 96
CAS No.1622427-14-8
Chemical FormulaC15H12N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Oxcarbazepine Impurity 101 structure
101
奥卡西平杂质101Oxcarbazepine Impurity 101
Oxcarbazepine Impurity 101
CAS No.353497-37-7
Chemical FormulaC17H15NO3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

奥卡西平 —— 研究文献与合成路线Oxcarbazepine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 奥卡西平 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Oxcarbazepine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Validated stability indicating reverse phase liquid chromatography method for oxcarbazepine and its degradation products with greenness evaluation
    Mestareehi A · Scientific reports · 2026
  2. A validated stability indicating LC method for oxcarbazepine
    Pathare DB, Jadhav AS, Shingare MS · Journal of pharmaceutical and biomedical analysis · 2007 · 被引 4cited 4
  3. Theoretical insights into the degradation mechanisms, kinetics and eco-toxicity of oxcarbazepine initiated by OH radicals in aqueous environments
    Sun Y, Li M, Hadizadeh MH, et al. · Journal of environmental sciences (China) · 2023 · 被引 10cited 10
  4. Freezing degradation of the anticonvulsant oxcarbazepine by bromate in water ice under sunlight irradiation
    Sun H, Zhang L, Dong D, et al. · The Science of the total environment · 2023 · 被引 8cited 8
  5. Appraisal of the greenness profile of a chromatographic method for the simultaneous estimation of carbamazepine and oxcarbazepine, along with two potential impurities and three formulation excipients
    Abdelwahab NS, Abdelrahman MM · RSC advances · 2021 · 被引 3cited 3
  6. Multi-heteroatom-doping promotes molecular oxygen activation on polymeric carbon nitride for simultaneous generation of H2O2 and degradation of oxcarbazepine
    Chen D, Yao B, Zhi X, et al. · Nanoscale · 2023

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF OXCARBAZEPINE
    KARUSALA NAGESWARA RAO, TUMMALAPALLY UMA SANKARA SASTRY, TALATALA APPI REDDY, DATTA DEBASHISH · 公开号 US2011065917US2011065917 · 2011
  2. AN IMPROVED PROCESS FOR THE PREPARATION OF OXCARBAZEPINE
    KARUSALA NAGESWARA RAO, TUMMALAPALLY UMA SANKARA SASTRY, TALATALA APPI REDDY, DATTA DEBASHISH · 公开号 WO2009139001WO2009139001 · 2009
  3. Modified release preparations containing oxcarbazepine and derivatives thereof
    BHATT PADMANABH P, KIDANE ARGAW, EDWARDS KEVIN · 公开号 US2011301147US2011301147 · 2011
  4. METHOD FOR CHEMICAL SYNTHESIS OF OXCARBAZEPINE
    SU WEIKE, LI JIANJUN, JIANG ZULIN, XU JIANKANG, et al. · 公开号 WO2010000196WO2010000196 · 2010
  5. METHOD FOR CHEMICAL SYNTHESIS OF OXCARBAZEPINE
    SU WEIKE, LI JIANJUN, JIANG ZULIN, XU JIANKANG, et al. · 公开号 EP2311812EP2311812 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

奥卡西平 杂质谱研究要点Oxcarbazepine — impurity profiling notes

下面这些是拿到 奥卡西平 的 38 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 38 impurity entries for Oxcarbazepine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances